HomeComparePSTTF vs ADC

PSTTF vs ADC: Dividend Comparison 2026

PSTTF yields 1379.31% · ADC yields 4.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PSTTF wins by $327926178.76M in total portfolio value
10 years
PSTTF
PSTTF
● Live price
1379.31%
Share price
$0.15
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$327926178.94M
Annual income
$286,995,341,463,684.70
Full PSTTF calculator →
ADC
Agree Realty Corporation
● Live price
4.13%
Share price
$74.97
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$178.9K
Annual income
$80,797.29
Full ADC calculator →

Portfolio growth — PSTTF vs ADC

📍 PSTTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPSTTFADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PSTTF + ADC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PSTTF pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PSTTF
Annual income on $10K today (after 15% tax)
$117,241.38/yr
After 10yr DRIP, annual income (after tax)
$243,946,040,244,131.97/yr
ADC
Annual income on $10K today (after 15% tax)
$351.36/yr
After 10yr DRIP, annual income (after tax)
$68,677.70/yr
At 15% tax rate, PSTTF beats the other by $243,946,040,175,454.28/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PSTTF + ADC for your $10,000?

PSTTF: 50%ADC: 50%
100% ADC50/50100% PSTTF
Portfolio after 10yr
$163963089.56M
Annual income
$143,497,670,772,241.00/yr
Blended yield
87.52%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

PSTTF
No analyst data
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+8.1% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PSTTF buys
0
ADC buys
0
No recent congressional trades found for PSTTF or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPSTTFADC
Forward yield1379.31%4.13%
Annual dividend / share$2.00$3.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$327926178.94M$178.9K
Annual income after 10y$286,995,341,463,684.70$80,797.29
Total dividends collected$324920394.51M$156.7K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: PSTTF vs ADC ($10,000, DRIP)

YearPSTTF PortfolioPSTTF Income/yrADC PortfolioADC Income/yrGap
1← crossover$148,631$137,931.03$10,990$580.36+$137.6KPSTTF
2$2,075,001$1,915,965.64$12,301$860.26+$2.06MPSTTF
3$27,218,680$24,998,428.97$14,104$1,298.62+$27.20MPSTTF
4$335,586,754$306,462,766.83$16,691$2,008.16+$335.57MPSTTF
5$3,890,354,077$3,531,276,249.42$20,580$3,205.09+$3890.33MPSTTF
6$42,421,557,343$38,258,878,480.81$26,754$5,330.02+$42421.53MPSTTF
7$435,284,512,667$389,893,446,310.20$37,196$9,345.14+$435284.48MPSTTF
8$4,204,696,744,549$3,738,942,315,995.26$56,244$17,523.09+$4204696.69MPSTTF
9$38,253,119,134,080$33,754,093,617,412.28$94,286$35,736.21+$38253119.04MPSTTF
10$327,926,178,937,150$286,995,341,463,684.70$178,949$80,797.29+$327926178.76MPSTTF

PSTTF vs ADC: Complete Analysis 2026

PSTTFStock

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.

Full PSTTF Calculator →

ADCREIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this PSTTF vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PSTTF vs SCHDPSTTF vs JEPIPSTTF vs OPSTTF vs KOPSTTF vs MAINPSTTF vs NNNPSTTF vs EPRTPSTTF vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.